SCHEMBL4912359

SCHEMBL4912359

CCCC(CC(=O)NCC1CC1)C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.46
FAAH O00519 1/20 0.40
BACE1 P56817 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 1/20 0.35
HDAC7 Q8WUI4 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
CNR2 P34972 5/20 0.33
CNR1 P21554 4/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
ADRA1A P35348 2/20 0.33
AKR1A1 P14550 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7371375 0.94 TSHR (0.41) TDP1FAAHBACE1CA1CA2
SCHEMBL7370650 0.94 TDP1 (0.40) TDP1FAAHBACE1CA1CA2
SCHEMBL7376546 0.91 CA2 (0.49) TDP1FAAHCA1CA2CNR2
SCHEMBL7368751 0.85 CA1 (0.46) TDP1FAAHBACE1CA1CA2
SCHEMBL7378250 0.85 CA1 (0.46) TDP1FAAHBACE1CA1CA2
SCHEMBL7377935 0.80 TDP1 (0.44) TDP1FAAHBACE1CNR2CNR1
SCHEMBL8424725 0.80 CA1 (0.42) TDP1FAAHCA1CA2SMN1; SMN2
SCHEMBL8424734 0.78 ALDH1A1 (0.35) TDP1CA1CA2ALDH1A1
SCHEMBL7374649 0.76 CYP2D6 (0.39) TDP1BACE1CA1CA2TSHR
SCHEMBL7374314 0.75 TDP1 (0.39) TDP1CA1CA2SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1102752-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION Du Pont Pharmaceuticals Company (US) 2001-05-30 EP claimed
WO-2000007995-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2000-02-17 WO claimed
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-27 US disclosed
EP-1102752-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION Du Pont Pharmaceuticals Company (US) 2001-05-30 EP disclosed
WO-2000007995-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BACE1, APH1A, APP TDP1 2065/4885FAAH 2456/4885BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.